Revolution Medicines (RVMD) Projected to Post Quarterly Earnings on Wednesday

Revolution Medicines (NASDAQ:RVMD - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Wednesday, May 7th. Analysts expect the company to announce earnings of ($1.10) per share for the quarter.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($1.12) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.11). On average, analysts expect Revolution Medicines to post $-3 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Revolution Medicines Stock Up 0.6 %

Shares of Revolution Medicines stock opened at $40.64 on Friday. The company has a market capitalization of $7.56 billion, a price-to-earnings ratio of -11.32 and a beta of 1.37. The stock's 50-day simple moving average is $37.35 and its 200-day simple moving average is $43.84. Revolution Medicines has a 52 week low of $29.17 and a 52 week high of $62.40.

Insider Activity at Revolution Medicines

In other news, COO Margaret A. Horn sold 3,058 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total value of $119,384.32. Following the sale, the chief operating officer now owns 153,533 shares of the company's stock, valued at approximately $5,993,928.32. This represents a 1.95 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Jack Anders sold 1,864 shares of Revolution Medicines stock in a transaction dated Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $72,770.56. Following the transaction, the chief financial officer now directly owns 115,006 shares of the company's stock, valued at approximately $4,489,834.24. This represents a 1.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 16,660 shares of company stock valued at $650,406. Insiders own 8.00% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on RVMD shares. UBS Group boosted their price target on Revolution Medicines from $65.00 to $71.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Wedbush reissued an "outperform" rating and issued a $67.00 target price on shares of Revolution Medicines in a report on Monday. HC Wainwright raised their target price on shares of Revolution Medicines from $72.00 to $73.00 and gave the company a "buy" rating in a research note on Monday, March 3rd. Stifel Nicolaus decreased their price target on shares of Revolution Medicines from $78.00 to $64.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Finally, Needham & Company LLC restated a "buy" rating and set a $59.00 price objective on shares of Revolution Medicines in a research report on Tuesday, April 8th. Twelve analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Revolution Medicines presently has a consensus rating of "Buy" and a consensus price target of $66.67.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.